PMEL and melanoma: This technique was subsequently explored in the study of TCR-like antibodies against peptide/MHC complexes derived from other tumor antigens, such as telomerase catalytic subunit [27], glycoprotein 100 (gp100) [23, 24], mucin 1 (MUC1) [28], human telomerase reverse transcriptase (hTERT) [27], NYESO-1 [29], MART-1 [34], preferentially expressed antigen in melanoma (PRAME) [45], tyrosinase [38], and WT1 [15].